HSD17B4 and neoplasm: In the univariate analysis for association between HSD17B4 expression and clinicopathological parameters, we found lack of significant association for adjuvant mitotane therapy (P = 0.092), tumor stage (P = 0.148), metastasis (P = 0.661), Weiss score (P = 0.143), response to primary therapy (P = 0.183), residual tumor status (P = 0.236), lymph node involvement (P = 0.578) or patient gender (P = 0.489).